UBS analyst Timothy Arcuri raised the firm’s price target on Teradyne (TER) to $120 from $110 and keeps a Buy rating on the shares. UBS sees in-line Q2 results and upside to Street estimates for Q3 guidance, despite consternation about Teradyne potentially cutting again, the analyst tells investors in a research note. The firm doesn’t expect much change in tone as management is likely to reiterate limited visibility and tariff-related uncertainty, but does see more of an upside bias to second half versus the Street.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TER:
- TER, META: Cathie Wood Continues to Bet Big on Robotics, Trims Stake in This Tech Stock
- TER, NVDA, AMD: Cathie Wood Makes Million-Dollar Bets on AI and Robotics
- Private Markets: JPMorgan initiates coverage of OpenAI
- Starbucks downgraded, Oracle initiated: Wall Street’s top analyst calls
- Teradyne downgraded to Neutral from Overweight at JPMorgan